Advenchen Laboratories is dedicated to advancing cancer treatment through the research and development of small molecule drugs, particularly focusing on small molecule kinase inhibitors. Their primary area of interest lies in protein tyrosine kinases (PTKs), which play a crucial role in the regulation of cellular processes related to cancer. The company has developed a proprietary pipeline of drug candidates that have shown significant anti-tumor activity and therapeutic potential across various cancer types. By innovating chemical fragments and scaffolds, Advenchen aims to enhance the solubility, pharmacodynamics, pharmacokinetics, and toxicology profiles of their drug candidates, thereby increasing the likelihood of successful preclinical and clinical outcomes.

Currently, Advenchen is engaged in multiple phase 3 clinical studies for their small molecule oncology products, which are at different stages of completion, including data lock and patient recruitment. The company is on track to submit its first New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in 2025, marking a significant milestone in their commitment to developing breakthrough therapies for cancer patients. Through their focused research efforts and innovative approach, Advenchen Laboratories is poised to contribute meaningful advancements in cancer treatment.

United States

Advenchen is a pharmaceutical company that focuses on small molecule cancer drug discovery programs with a specialization in protein kinase inhibitors.

Advenchen Laboratories

Company Details